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Abstract 
Hexamidine (HEX) has been used as a preservative in topical preparations since the 
1950s. A number of studies also indicate that the molecule plays a beneficial role in skin 
homeostasis. In this review we describe the physicochemical properties of hexamidine 
diisethionate (HEX D) and the corresponding hydrochloride salt (HEX H). The biocidal and 
protease inhibition properties of HEX are outlined as well as the effects of HEX on lipid 
processing enzymes, corneocyte maturity, stratum corneum thickness and Trans epidermal 
water loss (TEWL). Skin permeation properties of HEX D and HEX H are summarised and 
formulation approaches for effective dermal targeting of HEX are discussed.  
 
Key words: Hexamidine, salt, biocide, protease inhibitor, skin, formulation  
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Introduction 
Hexamidine (HEX) is a strong organic base and is an aromatic diamidine. Although 
hexamidine is primarily used as the diisethionate salt (HEX D), it was firstly synthesised as 
the dihydrochloride salt (HEX H) and patented for May & Baker Limited (U.K.), by Ewins et 
al.  [1] (1939). The company was interested in the promising trypanocidal activity of the 
aromatic diamidines and subsequently demonstrated that hexamidine dihydrochloride 
dihydrate (HEX H) was the most potent of all  compounds synthesised [2] (Ashley et al., 
1942). In the 1990’s the efficacy of HEX as an amoebicidal agent was demonstrated in a 
number of studies [3,4] (Brasseur et al., 1994; Perrine et al., 1995; Gray et al., 1996).  In 
addition to biocidal activity HEX and other diamidines have demonstrated enzyme inhibition 
properties [5] (Geratz et al., 1973). Upregulation of the major cholesterol and fatty acid 
uptake pathways has also been demonstrated in a skin equivalent tissue culture model 
following treatment with HEX [6] (Jarrold et al., 2010b). Surprisingly, until relatively 
recently very little information about the physicochemical properties and dermal disposition 
of HEX had been reported. The aims of this review are to (i) Summarise the physicochemical 
properties of hexamidine and its salts (ii) Outline the applications of HEX as a biocide (iii) 
Critically assess the studies which have investigated the potential benefits of HEX for skin 
health (iv) Identify appropriate dermatological vehicles for effective delivery of HEX to the 
skin.  
 
 
Physicochemical properties and analytical methods to quantify hexamidine 
diisethionate (HEX D) and hexamidine dihydrochloride (HEX H) 
 
Hexamidine diisethionate 
The salt of hexamidine with the strong organic isethionic acid, a member of the 
sulphonic acid series, is the only hexamidine derivative currently reported in the British 
Pharmacopoeia [7] (British Pharmacopoeia, 2014). The chemical structure, IUPAC name, 
chemical formula and molecular weight of hexamidine diisethionate (HEX D) are 
summarised in Figure 1.  
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HEX D is described in the British Pharmacopoeia 2015 monograph as a “white or 
slightly yellow powder, hygroscopic, sparingly soluble in water, slightly soluble in ethanol 
(96 per cent), practically insoluble in methylene chloride” [7]  (British Pharmacopoeia 
Commission, 2014). Recently we reported the characterisation of HEX D [8] (Parisi et al., 
2015) and described a number of physicochemical properties which have not been reported 
previously including solubility, melting point and Log D at pH 7.4 (Table 1). We also 
developed a new High Performance Liquid Chromatographic method for analysis of HEX D. 
Two other HPLC methods are described in the literature. The first was developed in order to 
quantify HEX D in various pharmaceutical formulations such as creams, ointments and 
eyewash solutions [9] (Taylor et al., 1983). The purpose of the second was the qualitative 
separation of HEX D from other actives with similar chemical structure and its quantification 
in a cosmetic cream [10] (De Bukanski and Masse, 1984). Since HEX D has typically been 
used in solution no variations in its crystal structure (polymorphism) had been reported until 
recently. Fucke et al. (2008) Fucke et al. [11] used X-ray crystallisation and thermal analysis 
to identify ten anhydrous crystal forms and two dihydrates of HEX D.  
 
 
 
 
Figure 1 Chemical structure, IUPAC name and chemical formula of HEX D    
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Table 1. Physicochemical properties of HEX D and HEX H [8] (Parisi et al., 2015) 
 HEX D HEX H 
Molecular weight 606.7 427.4 
Melting point (°C) 224.9 265.5 
Solubility (mg/mL), 32°C 52.0 16.0  
Log D(o/w)  pH 7.4 − 0.74 ± 0.02 − 0.70 ± 0.02 
pH in aqueous solution 6.3 – 6.4 6.3 – 6.4  
 
Hexamidine dihydrochloride 
As noted, hexamidine was first synthesised as the dihydrochloride salt in the late 
1930’s but, subsequently, the diisethionate salt was preferred for use, presumably because of 
its more favourable water solubility. The preparation and characterisation of HEX H (Figure 
2) was recently reported [8] (Parisi et al., 2015) and the physicochemical properties of the salt 
are summarised in Table 1. A new HPLC method was also developed for analysis of HEX H. 
With reference to topical delivery, HEX H has more favourable properties than HEX D, with 
a lower molecular weight and higher Log D value (pH 7.4). Consistent with these values,  we 
have recently demonstrated >70% delivery of HEX H to porcine skin, in vitro, using a simple 
binary mixture of propylene glycol and propylene glycol monolaurate [12] (Parisi et al., 
2016). In contrast, the maximum amounts of HEX D that could be delivered were of the order 
of 30%. 
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Figure 2. Chemical structure, IUPAC name and chemical formula of HEX H 
Applications and uses of hexamidine as a biocide 
As noted earlier, hexamidine was initially developed as a trypanocidal agent [1] (Ewins 
et al., 1939). The antiprotozoal activity of hexamidine was further explored more than 50 
years later when Brasseur et al. (1994) Brasseur et al. [3] successfully used HEX D to treat 
two subjects affected by Acanthamoeba keratitis. In addition, an in-vitro study from Perrine 
et al. (1995) Perrine et al. [4] showed that HEX D was effective not only against 
Acanthamoeba trophozoites but also against the dormant cyst forms. Bailly et al. (1997) 
Bailly et al. [13] thus hypothesised that the amoebicidal activity of hexamidine might have 
been directly related to its capacity to selectively bind DNA. However, although the study 
showed that HEX D strongly bound DNA, no correlation was found between the amoebicidal 
potency of the aromatic diamidines series and their DNA binding ability. In contrast, HEX D 
failed when used against an Acanthamoeba and Hartmannella corneal coinfection [14] 
(Aimard et al., 1998) and showed only limited efficacy on six subjects affected by chronic 
Acanthamoeba keratitis [15] (Pérez-Santonja et al., 2003).  
Interestingly, HEX H 2.5-hydrate was also found to be active against pneumonia 
induced in a rat model by a yeast-like fungus as Pneumocystis carinii [16] (Tidwell et al., 
1990). As observed earlier, for Acanthamoeba, DNA binding was proposed as a possible 
mechanism of action, but no direct correlation was observed between anti Pneumocystis 
carinii activity and DNA binding.  
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In terms of antibacterial properties, HEX D has been reported to be effective against 
Pseudomonas aeruginosa, Proteus, Escherichia coli, Staphylococcus aureus and 
Tsukamurella paurometabolum [17,18] (van Ketel, 1975; Granel et al., 1996). In addition, a 
more recent in-vitro study demonstrated the efficacy of HEX D against a series of multi-drug 
resistant gram-positive bacteria [19] (Grare et al., 2010).  
The exact mechanism of diamidine antibacterial efficacy, including HEX D, is still 
unclear. However, due to its native positive charge, it is thought that HEX D binds with high 
affinity to the negatively-charged cell walls and membranes of bacteria and that disruption is 
brought about by perturbations of these binding sites [20] (Kratzer et al., 2006), resulting in 
inhibition of oxygen uptake and induced leakage of amino acids. In this sense, HEX D might 
be considered to be acting as a cationic surface-active agent [21] (McDonnell & Russell, 
1999).  
Contrasting antibacterial efficacy was reported by Murray et al. [22] Murray et al. 
(2004) who claimed that HEX D was both an inducer and substrate of the Staphylococcus 
aureus multidrug efflux transporter. Furthermore, Lemaître et al. [23] Lemaître et al. (1998) 
identified 14 strains of Listeria resistant to HEX D. The authors attributed this resistance to 
plasmid-mediated acquisition of a Staphylococcus aureus replicon.  
The impact of HEX D on human cutaneous microbiota has been investigated by Michel 
et al. [24] Michel et al. (1986) and Chevalier and Cremieux [25] Chevalier and Crémieux 
(1992). Both research groups concluded that HEX D is an effective and fast-acting antiseptic. 
However, while Michel et al. [24]  Michel et al. (1986) reported a marked disturbance of the 
skin microbiota, only slight modifications of the bacterial population were observed by 
Chevalier and Cremieux [25]  Chevalier and Crémieux (1992).  
In line with the broad spectrum of antimicrobial activity shown by hexamidine in its 
various forms, the European Union Cosmetics Directive 76/768/EEC, Annex VI, allows HEX 
D as a preservative for cosmetics and toiletries up to a maximum concentration of 0.10% [26] 
(European Economic Community 2001). Furthermore, in a submission by the US Cosmetics, 
Toiletries and Fragrances Association to the FDA in 2002, HEX D was listed as a 
preservative in 38 cosmetic products [27-29] (FDA, 2002; CTFA 2004;Cosmetic Ingredient 
Review Expert Panel, 2007). 
 
 
Hexamidine as an enzyme inhibitor 
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The aromatic diamidines series has also been studied to determine any enzyme 
inhibition properties. Geratz et al. [5] Geratz et al. (1973) examined their ability to inhibit 
trypsin, pancreatic kallikrein and thrombin; HEX H dihydrate was effective against all 
enzymes with reported Ki values of 1.9, 4.5 and 7.4 µM, respectively. Enyedy et al. [30] 
Enyedy et al. (2001) confirmed hexamidine inhibitory activity against thrombin although a 
considerably lower Ki value (224 nM) was reported; however these authors did not specify if 
the active was used as the free base or salt form. Furthermore, the study demonstrated that 
hexamidine was able to inhibit matriptase (Ki = 924 nM), a trypsin-like serine protease 
involved in tissue remodelling, cancer invasion and metastasis. Finally, an in-vivo study 
performed by Morgant et al. [31] Morgant et al. (1998) investigated the effect of two 
hexamidine salts on nitric oxide synthase (NOS). Surprisingly, while the diisethionate salt 
significantly decreased NOS activity, the tetrachloroplatinate (II) salt had no effect on NO 
generation. 
 
Hexamidine and skin biology 
Kimball et al. (2012) Kimball et al. [32] speculated that hexamidine might attenuate the 
skin ageing process because of its inhibitory activity on serine proteases associated with skin 
inflammation. Both skin inflammation and abnormal lipid biosynthesis have been linked to 
skin ageing [33]  (McGrath et al., 2012). Osborne et al. [34] and Jarrold et al. [6] Osborne et 
al. (2009) and Jarrold et al. (2010b) showed that the application of hexamidine in human skin 
equivalent cultures was able to reverse a series of cellular processes which are typical of aged 
skin. These processes included the downregulation of cholesterol, fatty acid and sphingolipid 
biosynthesis, the downregulation of cholesterol and fatty acid uptake and the upregulation of 
cholesterol efflux. Other studies have highlighted the ability of hexamidine to enhance the 
barrier properties of stratum corneum. Jarrold et al. [35] Jarrold et al. (2010a), for example, 
demonstrated that the application of a cosmetic moisturiser containing hexamidine, 
niacinamide and Pal-KT significantly increased the number and size of mature corneocytes of 
the facial stratum corneum of twenty female subjects. A further study showed a significant 
thickening and a concurrent reduction in transepidermal water loss (TEWL) for the volar 
forearm in 36 female subjects, following treatment with a cream containing hexamidine and 
niacinamide [36]  (Kaczvinsky et al., 2010).  
 
Safety of hexamidine with reference to skin application  
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The European Union Cosmetics Directive 76/768/EEC, Annex VI, allows HEX D as a 
preservative for cosmetics and toiletries up to a maximum concentration of 0.10% [26] 
(European Economic Community 2001). The safety of hexamidine and HEX D was assessed 
by the Cosmetic Ingredient Review Expert Panel [29] Cosmetic Ingredient Review Expert 
Panel (2007), which concluded that both actives are safe when used in cosmetics at 
concentrations less than or equal to 0.10%. This opinion was subsequently confirmed by the 
European Parliament and the Council of European Union [37] European Parliament and the 
Council of European Union (2009) which fixed the maximum allowed concentration of 
hexamidine and its salts in cosmetic products at 0.10%. Nevertheless, several cases of allergic 
contact dermatitis have been reported with hexamidine and the first was reported by 
Gougerot et al. [38] Gougerot et al. (1950). Sidi et al. [39] Sidi et al. (1969) observed 147 
cases of sensitization to HEX D in 8 years. Further cases were described by van Ketel [17], 
Robin [40], Dooms-Goosens et al. [41] and Brand and Ballmer-Weber [42].  van Ketel 
(1975), Robin (1978), Dooms-Goossens et al. (1989) and Brand and Ballmer-Weber (1995). 
One case of particular interest was reported by Mullins [43] Mullins (2006) who observed an 
allergic systemic reaction due to topical application of HEX D. Furthermore, in a study aimed 
at comparing 75 cases of contact dermatitis caused by antiseptics, hexamidine was the 
strongest sensitizer with 20 positive patch tests [44] (Barbaud et al., 2005). However, studies 
which involve larger numbers of subjects have shown that sensitization to hexamidine is not a 
common phenomenon. For example, Roul et al. [45] Roul et al. (1999) tested 269 children 
aged 3 to 15 years with 34 allergens and attributed only 1 allergic reaction to hexamidine. In 
a larger study, 641 children less than 16 years of age with atopic dermatitis were patch tested 
with 7 actives which are commonly used for the topical treatment of this disease [46] 
(Mailhol et al., 2009). The results showed that HEX D caused allergic contact dermatitis to 
only 3 children (0.5% of tested population). It can thus be concluded that hexamidine and its 
salts are generally safe to use, but adverse reactions are possible because of their skin-
sensitizing properties. 
 
Topical delivery of hexamidine salts to the skin  
Dermal absorption of HEX in human skin has not been studied extensively but a 
number of studies have been conducted in other models for toxicity and irritation evaluation. 
In vitro penetration of HEX from gel (0.1%) or cream (0.1, 0.3%) formulations was 
investigated in human cadaver skin using Franz cells [29] (Cosmetic Ingredient Review 
Expert Panel, 2007).  Following finite dose application, 0.027% of HEX in the gel 
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formulation penetrated the skin samples in 72 h. In the 0.1% and 0.3% water-oil 
formulations, 0.0321% and 0.0208% of the HEX dose, respectively, penetrated the skin 
samples in 72 h. The authors suggested the low skin penetration observed in this study 
indicated that bioavailability of HEX  from topical cosmetic formulations would be minimal 
 
Recently we outlined a rational formulation approach for effective targeting of HEX D 
and HEX H to the skin [12] (Parisi et al., 2016). Based on the solubility data reported in our 
earlier study [8] (Parisi et al., 2015), propylene glycol (PG), glycerol and PEG 200 were 
confirmed as suitable solvents. In addition to individual solvents, binary systems which 
combined the solvents with other chemical penetration enhancers (CPEs) were prepared and 
evaluated. CPEs were selected based on compatibility with PG, glycerol and PEG 200 and 
their reported applications in dermal formulations [47] (Lane, 2013). Candidate vehicles were 
evaluated using porcine skin mounted in in vitro Franz cells. The solvents and CPEs 
examined were dimethyl isosorbide (DMI), glycerol, isopropyl alcohol (IPA), 1,2-pentanol 
(1,2-PENT), polyethylene glycol (PEG) 200, propylene glycol (PG), propylene glycol 
monolaurate (PGML) and Transcutol
®
P (TC). Formulations containing PGML were 
particularly efficacious compared with other solvents or binary combinations. A binary 
system of PG:PGML (50:50) delivered ~70% of HEX H to the skin and also promoted skin 
penetration of HEX D (30%).  
 
Conclusions 
Although HEX was originally synthesised as the dihydrochloride salt, today it is the 
diisethionate form which is used in personal care products. The comprehensive characterisation 
of the physicochemical properties of both salts should facilitate the future development of novel 
formulations for topical delivery of HEX. Despite the fact that HEX H has more suitable 
properties for skin permeation than HEX D, in vitro permeation data indicate no advantage of the 
dihydrochloride salt over the diisethionate for dermal delivery. To date, HEX has been shown to 
affect biomarkers of skin barrier function, such as corneocyte size and maturity, lipid biosynthesis 
and uptake, increase stratum corneum thickness, reduce TEWL and modulate the activity of 
serine proteases associated with inflammation and turnover of the skin. However, further studies 
at the molecular level are needed to probe the interaction of HEX with cellular processes. HEX is 
incorporated in extremely low amounts in consumer products and it would also be interesting to 
examine any dose response effects in vitro and/or in vivo.  
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